# US 2013/0156729 A1 · Mammalian Receptor Proteins; Related Reagents and Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156729 A1
- Document ID: US20130156729A1
- Status: Published application
- Kind: A1
- Application number: 13/762,133
- Filed: 2013-02-07
- Published: 2013-06-20
- Earliest claimed: 2000-05-10
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Madaline Chirica; Robert A. Kastelein; Kevin Moore; Christi L. Parham
- Web page: https://patentgrep.com/patent/US20130156729A1

## CPC

- A61K 38/20: Interleukins [IL]
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/54: Interleukins [IL]
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G01N 33/6869: {Interleukin}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

## Claims

### Claim 1

A method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an agonist or antagonist of DCRS5 (SEQ ID NOs:1 or 2) or of p19 (SEQ ID NOs:5 or 6), wherein the disorder comprises:
a) rheumatoid arthritis;
b) asthma or allergy;
c) chronic obstructive pulmonary disorder (COPD);
d) an interstitial lung disorder;
e) an inflammatory bowel disorder (IBD); or
f) an inflammatory skin disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the skin disorder is:
a) psoriasis; or
b) atopic dermatitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the IBD is:
a) Crohn's disease; or
b) ulcerative colitis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the interstitial lung disorder is:
a) idiopathic pulmonary fibrosis;
b) eosinophilic granuloma; or
c) hypersensitivity pneumonitis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antagonist comprises a binding composition derived from the antigen binding site of an antibody that specifically binds to:
a) DCRS5 (SEQ ID NO:2); or
b) p19 (SEQ ID NO:6).

### Claim 6 (depends on 5)

The method of claim 5, wherein the binding composition comprises:
a) a polyclonal antibody;
b) a monoclonal antibody;
c) a humanized antibody; or
d) an Fab, Fv, or F(ab′)2 fragment.

### Claim 7 (depends on 1)

The method of claim 1, wherein the agonist comprises:
a) DCRS5 (SEQ ID NO:2); or
b) p19 (SEQ ID NO:6).

### Claim 8 (depends on 1)

The method of claim 1, wherein the agonist or antagonist comprises a nucleic acid.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antagonist comprises:
a) an antisense nucleic acid; or
b) an RNA interference nucleic acid.

### Claim 10

A method of diagnosing a physiological disorder comprising contacting a binding composition that specifically binds to DCRS5 (SEQ ID NOs:1 or 2), or to p19 (SEQ ID NOs:5 or 6), to a sample derived from a test subject experiencing:
a) rheumatoid arthritis;
b) asthma or allergy;
c) chronic obstructive pulmonary disorder (COPD);
d) an interstitial lung disorder;
e) inflammatory bowel disorder (IBD); or
f) an inflammatory skin disorder.

### Claim 11 (depends on 10)

The method of claim 10, further comprising:
a) contacting the binding composition to a sample derived from a control subject or control sample; and
b) comparing the binding found with the test subject with the binding found with the control subject or control sample.

### Claim 12 (depends on 10)

The method of claim 10, wherein the binding composition comprises:
a) a polyclonal antibody;
b) a monoclonal antibody;
c) a humanized antibody;
d) an Fab, Fv, or F(ab′)2 fragment;
e) a nucleic acid; or
f) a detectable label.

### Claim 13 (depends on 12)

The method of claim 12, wherein the nucleic acid comprises:
a) a probe or primer; or
b) a molecular beacon.

### Claim 14 (depends on 10)

The method of claim 10, wherein the sample is derived from a human cell, tissue, or biological fluid.

### Claim 15 (depends on 10)

The method of claim 10, wherein the skin disorder is:
a) psoriasis; or
b) atopic dermatitis.

### Claim 16 (depends on 10)

The method of claim 10, wherein the IBD is:
a) Crohn's disease; or
b) ulcerative colitis.

### Claim 17 (depends on 10)

The method of claim 10, wherein the interstitial lung disorder is:
a) idiopathic pulmonary fibrosis;
b) eosinophilic granuloma; or
c) hypersensitivity pneumonitis.
